Research Interests
I am a clinical investigator. I develop new therapies for people with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes and myeloproliferative neoplasms, including chronic myeloid leukemia. I have been the principal investigator for phase I, II and III studies.
Selected Grants
Study of AZD3632 Monotherapy or in Combination with Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or other Genotypes Associated with HOX Overexpression.
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2030An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-risk Myelodysplastic Syndromes (LR-MDS) Who are Relapsed/Refractory/Resistant to Prior Therapies.
Clinical TrialPrincipal Investigator · Awarded by Rigel Pharmaceuticals, Inc. · 2025 - 2030Studies to Assess Ziftomenib in Combination with Ven+Aza or 7+3 in Patients with Untreated NPM1-m or KMT2A-r AML
Clinical TrialPrincipal Investigator · Awarded by Kura Oncology, Inc. · 2025 - 2030A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Clinical TrialPrincipal Investigator · Awarded by SWOG-Clinical Trial Partnership, LLC · 2025 - 2030A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY AND ADMINISTERED AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD NEGATIVE AC
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2025 - 2030Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Clinical TrialPrincipal Investigator · Awarded by Kura Oncology · 2024 - 2029CL04-ORY-1001
Clinical TrialPrincipal Investigator · Awarded by Oryzon Genomics SA · 2023 - 2028Novartis Phase II MBG453 in combination with Venetoclax and Azacitidine in AML
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2028MacroGenics MGD024-01: A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies
Clinical TrialPrincipal Investigator · Awarded by MacroGenics, Inc. · 2023 - 2028HM-FLTI-101
Clinical TrialPrincipal Investigator · Awarded by Aptose Biosciences Inc. · 2023 - 2028AG946-C-002
Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2022 - 2027ASTX030-01
Clinical TrialPrincipal Investigator · Awarded by Astex Pharmaceuticals, Inc · 2022 - 2027DSP5336-101
Clinical TrialPrincipal Investigator · Awarded by Sumitomo Dainippon Pharma Co. · 2022 - 2027Racial and Ethnic Differences in the Real-World Clinical Outcomes of IDH1 and IDH2 Inhibitors in Acute Myeloid Leukemia
ResearchMentor · Awarded by University of North Carolina - Chapel Hill · 2024 - 2026SWOG / NCORP Research Base
Clinical TrialPrincipal Investigator · Awarded by Oregon Health & Science University · 2019 - 2026A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML
Clinical TrialPrincipal Investigator · Awarded by Ascentage Pharma Group · 2021 - 2026SWOG - CTP Purchase Service Agreement - Non Federal
Clinical TrialPrincipal Investigator · Awarded by SWOG-Clinical Trial Partnership, LLC · 2021 - 2026A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Clinical TrialPrincipal Investigator · Awarded by Kura Oncology · 2021 - 2026SWOG / NCTN Network Group Operations Center - Federal
Clinical TrialPrincipal Investigator · Awarded by Oregon Health & Science University · 2019 - 2026NCTN Network Group Operations Center
ResearchPrincipal Investigator · Awarded by Oregon Health & Science University · 2019 - 2026NCI National Clinical Trials Network (UG1)
Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 2019 - 2026ImmunoGen_0802: Ph 1b/2 IMGN632
Clinical TrialPrincipal Investigator · Awarded by ImmunoGen, Inc. · 2020 - 2026ALX Oncology: I/II of ALX148 in combo with Aza in patients with higher risk MDS
Clinical TrialPrincipal Investigator · Awarded by ALX Oncology · 2020 - 2025A PHASE I STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF ORALLY ADMINISTERED APG-2575 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Clinical TrialPrincipal Investigator · Awarded by Ascentage Pharma Group · 2019 - 2025SWOG Network Group Operations Center of the NCTN
Clinical TrialPrincipal Investigator · Awarded by Oregon Health & Science University · 2019 - 2025ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naive Patients with Higher Risk Myelodysplastic Syndrome
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2020 - 2025A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Clinical TrialPrincipal Investigator · Awarded by GlycoMimetics, Inc · 2018 - 2024AT148005
Clinical TrialPrincipal Investigator · Awarded by ALX Oncology · 2021 - 2024Agios MDS and Organ Impairment study
Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2020 - 2024R21 Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia
ResearchCollaborator · Awarded by National Institutes of Health · 2021 - 2024Jazz 1b CPX-351 previously untreated AML
Clinical TrialPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2020 - 2024GS-US-546-5857
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2023 - 2024Ph1b in patients with Hem Malignancies
Clinical TrialPrincipal Investigator · Awarded by Forty Seven, Inc. · 2020 - 2024Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias
Clinical TrialPrincipal Investigator · Awarded by PTC Therapeutics, Inc · 2020 - 2024A PHASE 1 STUDY OF DS-3032B IN COMBINATION WITH QUIZARTINIB IN SUBJECTS WITH FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA THAT ARE RELAPSED/REFRACTORY, OR NEWLY DIAGNOSED AND UNFIT FOR INTENSIVE CHEMOTHERAPY
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2019 - 2024A phase Ib, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2024A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2020 - 2024A Phase I Study of DS-3201B in Subjects With Acute Myelogenous Leukemia (AML) Or Acute Lymphocytic Leukemia (ALL)
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2018 - 2024A phase 1, Multi-center, open-label study of IMGN632 administered intravenously in patients with relapsed/refractory CD123-positive acute myeloid leukemia and other CD123-positive hematologic mali
Clinical TrialPrincipal Investigator · Awarded by ImmunoGen, Inc. · 2018 - 2024Kronos | KB-ENTO-3001
Clinical TrialPrincipal Investigator · Awarded by Kronos Bio, Inc · 2022 - 2024A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL
Clinical TrialPrincipal Investigator · Awarded by Servier Pharmaceuticals · 2021 - 2023Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2018 - 2023Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Clinical TrialPrincipal Investigator · Awarded by Takeda Pharmaceutical Company Limited · 2021 - 2023A Phase I/Ib, Multicenter, Open-Label, Dose-Escalation Study of FT-2102 as a Single agent and in Combination with Azacitidine in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Clinical TrialPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2018 - 2023A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination with Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2022 - 2022A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD 123 X CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Clinical TrialPrincipal Investigator · Awarded by MacroGenics, Inc. · 2015 - 2022SWOG Network Group Operations Center of the NCTN
ResearchPrincipal Investigator · Awarded by Oregon Health & Science University · 2018 - 2019External Relationships
- AbbVie, Inc.
- Bristol-Myers Squibb
- Daiichi Sankyo Co., Ltd
- Glycomimetics
- Incyte
- Jazz Pharmaceuticals
- Kura Oncology
- Servier
- Sumitomo Dainippon Pharma Oncology
- Syndax
- Thermo Fischer
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.